SCHEMBL1760652

SCHEMBL1760652

O=c1c2ccccc2[s+]([O-])[s+]1[O-]

nearest known ligand 0.32

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.31
KDM4E B2RXH2 2/20 0.30
ALDH1A1 P00352 2/20 0.30
GLA P06280 2/20 0.30
HPGD P15428 2/20 0.30
SMN1; SMN2 Q16637 2/20 0.30
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
HTT P42858 1/20 0.30
ATM Q13315 1/20 0.30
CYP3A4 P08684 1/20 0.30
MAPT P10636 1/20 0.30
PGAM1 P18669 1/20 0.30
MAOA P21397 1/20 0.30
CASP1 P29466 1/20 0.30
CASP7 P55210 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL472592 0.68 ALDH1A1 (0.41) KDM4EALDH1A1GLAHPGDSMN1; SMN2
SCHEMBL205562 0.66 CYP2A6 (0.33) ALDH1A1HSD17B10
SCHEMBL30286606 0.66 CYP2A6 (0.33) ALDH1A1HSD17B10
SCHEMBL816303 0.64 KDM4E (0.37) PARP1KDM4EALDH1A1GLAHPGD
SCHEMBL12269543 0.59 ALDH1A1 (0.41) KDM4EALDH1A1GLAHPGDSMN1; SMN2
SCHEMBL3142984 0.57 ALDH1A1 (0.39) KDM4EALDH1A1GLAHPGDSMN1; SMN2
SCHEMBL13326153 0.57 ALDH1A1 (0.39) KDM4EALDH1A1GLAHPGDSMN1; SMN2
SCHEMBL4311602 0.57
SCHEMBL927812 0.57 ALDH1A1 (0.50) PARP1KDM4EALDH1A1GLAHPGD
SCHEMBL2472141 0.56 CA12 (0.32) ALDH1A1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1483280-B1 FLUORESCENT NITROGENOUS BASE AND NUCLEOSIDES INCORPORATING SAME GLEN RES CORP (US) 2012-10-24 EP disclosed
US-7947459-B2 Human Six Transmembrane Epithelial Antigen of the Prostate (STEAP) protein; folds in a \"serpentine\" manner into three extracellular and two intracellular loops; used for diagnosis and treatment of prostate cancer AGENSYS, INC. (US) 2011-05-24 US disclosed
EP-1483280-A4 FLUORESCENT NITROGENOUS BASE AND NUCLEOSIDES INCORPORATING SAME GLEN RES CORP (US) 2007-05-02 EP disclosed
US-7144995-B2 Fluorescent nitrogenous base and nucleosides incorporating same GLEN RESEARCH CORPORATION (US) 2006-12-05 US disclosed
US-20060020113-A9 Serpentine transmembrane antigens expressed in human cancers and uses thereof HUBERT RENE S 2006-01-26 US disclosed
US-20050004349-A1 Serpentine transmembrane antigens expressed in human cancers and uses thereof HUBERT RENE S (US) 2005-01-06 US disclosed
EP-1483280-A2 FLUORESCENT NITROGENOUS BASE AND NUCLEOSIDES INCORPORATING SAME Glen Research Corporation (US) 2004-12-08 EP disclosed
US-20040009933-A1 Fluorescent nitrogenous base and nucleosides incorporating same GLEN RESEARCH CORPORATION (US) 2004-01-15 US disclosed
WO-2003077215-A2 FLUORESCENT NITROGENOUS BASE AND NUCLEOSIDES INCORPORATING SAME GLEN RESEARCH CORPORATION (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009933-A1 Fluorescent nitrogenous base and nucleosides incorporating same NUDT1, NT5C3B, NCL PARP1 655/4885KDM4E 4706/4885ALDH1A1 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.